Oxurion NV – LSE:0G99.L
Oxurion NV stock price today
Oxurion NV stock price monthly change
Oxurion NV stock price quarterly change
Oxurion NV stock price yearly change
Oxurion NV key metrics
Market Cap | 667.52K |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.39 |
Revenue | 858K |
EBITDA | -35.88M |
Income | -50.65M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -4181.93% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOxurion NV stock price history
Oxurion NV stock forecast
Oxurion NV financial statements
| Jun 2022 | 260K | -14.48M | -5570.77% |
|---|---|---|---|
| Dec 2022 | 335K | -17.20M | -5134.63% |
| Jun 2023 | 180K | -10.62M | -5901.67% |
| Dec 2023 | 83K | -8.34M | -10055.42% |
| 2025 | 1M | -925.17M | -92517.04% |
|---|---|---|---|
| 2026 | 30.28M | -1.98B | -6547.25% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 11993000 | 16.57M | 138.21% |
|---|---|---|---|
| Dec 2022 | 11993000 | 16.57M | 138.21% |
| Jun 2023 | 11820000 | 20.44M | 172.95% |
| Dec 2023 | 6550000 | 19.73M | 301.31% |
| Jun 2022 | -14.85M | 23K | 8.81M |
|---|---|---|---|
| Dec 2022 | -5.16M | 83K | 4.82M |
| Jun 2023 | -7.11M | 66K | 5.73M |
| Dec 2023 | -2.96M | 4K | 2.40M |
Oxurion NV alternative data
| Aug 2023 | 27 |
|---|---|
| Sep 2023 | 27 |
| Oct 2023 | 27 |
| Nov 2023 | 20 |
| Dec 2023 | 20 |
| Jan 2024 | 20 |
| Feb 2024 | 20 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Oxurion NV other data
| Patent |
|---|
Application Filling date: 19 Aug 2019 Issue date: 1 Jul 2021 |
Application Filling date: 19 Aug 2019 Issue date: 20 Feb 2020 |
| Insider | Compensation |
|---|---|
Dr. Patrik De Haes Chief Executive Officer & Executive Director | $557,000 |
Mr. Wouter Piepers Global Head of Corporation Communications & Investor Relations | |
Marc Denayer Global Head of Drug Safety & Medical Affairs | |
Julie Binon Head of HR | |
| Mr. Thomas Graney Chief Financial Officer | |
Mr. Jean Feyen Chief Scientific Officer | |
Dr. Andy De Deene Global Head of Devel. | |
Mr. Ove Pedersen Head of Product Supply | |
Ms. Vinciane Vangeersdaele Chief Commercial Officer | |
Dr. Grace Chang M.D., Ph.D. Chief Medical Officer |
-
What's the price of Oxurion NV stock today?
One share of Oxurion NV stock can currently be purchased for approximately $4.88.
-
When is Oxurion NV's next earnings date?
Unfortunately, Oxurion NV's (0G99.L) next earnings date is currently unknown.
-
Does Oxurion NV pay dividends?
No, Oxurion NV does not pay dividends.
-
How much money does Oxurion NV make?
Oxurion NV has a market capitalization of 667.52K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 55.8% to 263K US dollars.
-
What is Oxurion NV's stock symbol?
Oxurion NV is traded on the LSE under the ticker symbol "0G99.L".
-
What is Oxurion NV's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Oxurion NV?
Shares of Oxurion NV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Oxurion NV's key executives?
Oxurion NV's management team includes the following people:
- Dr. Patrik De Haes Chief Executive Officer & Executive Director()
- Mr. Wouter Piepers Global Head of Corporation Communications & Investor Relations
- Marc Denayer Global Head of Drug Safety & Medical Affairs
- Julie Binon Head of HR
- Mr. Thomas Graney Chief Financial Officer
- Mr. Jean Feyen Chief Scientific Officer
- Dr. Andy De Deene Global Head of Devel.
- Mr. Ove Pedersen Head of Product Supply
- Ms. Vinciane Vangeersdaele Chief Commercial Officer
- Dr. Grace Chang M.D., Ph.D. Chief Medical Officer
-
How many employees does Oxurion NV have?
As Jul 2024, Oxurion NV employs 20 workers.
-
When Oxurion NV went public?
Oxurion NV is publicly traded company for more then 17 years since IPO on 6 Aug 2008.
-
What is Oxurion NV's official website?
The official website for Oxurion NV is oxurion.com.
-
How can i contact Oxurion NV?
Oxurion NV can be reached via phone at +32 16 75 13 10.
Oxurion NV company profile:
Oxurion NV
oxurion.comLSE
20
Medical - Pharmaceuticals
Healthcare
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Leuven, 3001
:
ISIN: BE0003846632
:
